Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response

Figures

• 

  Figure 1. Antibody response following the BNT162b2 vaccine was greater in younger vaccinees. (A) Age distribution of study participants. (B) SARS-CoV-2 IgG levels across different age groups (Kruskal–Wallis One Way Analysis of Variance on Ranks: p < 0.01). (C) SARS-CoV-2 IgG levels in females and males (Mann–Whitney U test: p > 0.05). A positive response is defined as ≥50 AU/mL.

• 

  Figure 2. Adverse reactions shift from no/local reactions to systemic following the 2nd vaccine dose. (A) The distribution of the various types of reactions- none, local or systemic, following each vaccination dose (Chi-square, p < 0.001). (B,C) The majority of adverse reactions following the 2nd vaccine dose were systemic for both females (Chi-square, p < 0.001) and males (Chi-square, p < 0.01).

• 

  Figure 3. Association between SARS-CoV-2 IgG antibody response and adverse reactions. SARS-CoV-2 IgG levels in vaccinees who experienced no adverse reactions, isolated local adverse reactions, or any systemic adverse reaction (A) following either dose (Kruskal–Wallis One Way Analysis of Variance on Ranks: p < 0.001), (B) the first dose (Kruskal–Wallis One Way Analysis of Variance on Ranks: p < 0.05) or (C) the second dose (Kruskal–Wallis One Way Analysis of Variance on Ranks: p < 0.001). A positive response is defined as ≥50 AU/mL.